New drug QLS5316 enters first human tests for advanced cancers
NCT ID NCT07358884
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a new drug called QLS5316 in about 300 adults with advanced solid tumors (such as colorectal, stomach, head and neck, or lung cancer) that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see early signs of whether it shrinks tumors. Participants receive QLS5316 alone and are closely monitored for side effects and lab changes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Digital peer support: a new weapon against cancer treatment anxiety?
- Can a plasma beam stop colon polyps from coming back?
- Can AI-Guided home training boost recovery from gastric cancer surgery?
- A stitch in time: could a device make abdominal closure safer?
- Can your own immune cells beat advanced cancer?
- Can we predict chemo brain before it happens?